根据重整方案，皖维集团将通过"直接收购股票+保留股票"的方式，合计控制杉杉股份21.88%的表决 权，投资总额上限不超过71.56亿元。 其中，皖维集团以每股约16.42的价格，直接收购杉杉股份13.50%的股权，对应总价款约49.87亿元；剩 余8.38%的股份在限售期内（约36个月）仍由债务人持有，但需与皖维集团保持一致行动，皖维集团同 步配套提供即期出资和远期收购方案供债权人选择，同时承诺通过重整取得的股票自愿锁定36个月。 值得一提的是，本次重整还将设立一个破产服务信托，其受益人为皖维集团、债权人和原出资人，底层 资产包括继续保留在债务人名下的股票，以及除杉杉股份股票外的全部其他资产。宁波金资将担任第一 任处置机构。 历时近一年的杉杉集团重整案迎来关键节点。 公告发布后的第二天，公司股价迎来强势涨停。不过，股价在今日出现回落调整，截至今日收盘，杉杉 股份报15.12元/股，较前一交易日收盘价下跌4.36%，总市值340.1亿元。 2月8日晚，杉杉股份发布公告称，其控股股东杉杉集团及其全资子公司朋泽贸易，与重整投资人皖维集 团、宁波金资正式签署《重整投资协议》。 公开资料显示，杉杉股份成立于1989年， ...

2月10日，AI语料概念迎来集体爆发行情。东方财富数据显示，截至收盘，AI语料板块指数涨幅超 7%。其中，读客文化、捷成股份、中文在线、荣信文化20cm涨停，华策影视、果麦文化涨超10%，国 安股份、新华网、人民网、掌阅科技、视觉中国等10cm涨停，中信出版、慈文传媒、芒果超媒等涨超 5%。 中银证券指出，当前市场情绪已处于低点，大模型"春节档"带来密集产业催化，Seedance2.0 带动AI多 模态产业链，各项因素有望催化AI应用触底反弹。 语料加工与影视素材类公司同样迎来需求增量。捷成股份主营业务包含新媒体版权运营，其在影视拍摄 中产生的大量素材，可通过清洗、标注等加工处理成为优质AI语料，为Seedance 2.0等模型提供训练支 撑，公司明确表示相关素材具备极高的语料利用潜力。视觉中国则为Seedance 2.0提供正版图片训练数 据及版权合规服务，成为模型语料合规化的重要支撑。 在影视IP运营与内容变现领域，上海电影、博纳影业等头部影视公司凭借与即梦AI的深度战略合作， 成为核心受益者。 在算力与数据服务领域，Seedance 2.0的规模化应用也间接带动相关公司需求。作为字节跳动第一大 IDC/ ...

2月9日晚间，中科曙光发布公告，宣布拟向不特定对象发行可转换公司债券，募集资金总额不超过80亿 元，分别投入面向人工智能的先进算力集群系统项目、下一代高性能AI训推一体机项目和国产化先进 存储系统项目，进一步巩固公司在高端计算与人工智能领域的布局。 对于本次发行的影响，中科曙光表示，公司将丰富产品矩阵，强化从硬件设备到软件平台、从基础设施 到运营服务的全栈能力，助力公司在智能算力、国产化存储等高附加值领域抢占市场先机。 值得一提的是，本次募资前，中科曙光已在算力领域持续发力。2月5日，公司提供的3套万卡超集群系 统在国家超算互联网郑州核心节点同时上线试运行，建成国内最大国产AI算力池，可覆盖万亿参数模 型训练等多类AI计算场景。 在AI爆发式增长的推动下，中科曙光的业绩也开始释放。2023年，公司营业总收入达143.53亿元，归母 净利润18.36亿元，经营活动现金流净额大幅增长212.02%；2024年，公司全年实现营业总收入131.48亿 元，归母净利润19.11亿元。2025年前三季度，实现营业收入88.2亿元，同比增长9.68%；归母净利润 9.66亿元，同比增长25.55%。 下一代高性能AI训推一 ...

Core Viewpoint - Yongtai Technology plans to acquire a 25% stake in Yongtai High-tech held by CATL through a share issuance, which will make Yongtai High-tech a wholly-owned subsidiary of Yongtai Technology, enhancing collaboration between the two companies [1][3] Group 1: Transaction Details - Yongtai Technology currently holds a 75% stake in Yongtai High-tech, and if the transaction is completed, CATL will become a shareholder of Yongtai Technology [1] - Yongtai Technology's stock will be suspended from trading starting February 9, with a specific transaction plan expected to be disclosed within 10 trading days [1] Group 2: Historical Context - The acquisition is not the beginning of the partnership; in November 2021, Yongtai High-tech's shareholder transferred a 25% stake to CATL for 500 million yuan, marking CATL's entry as an industrial investor [2] - Yongtai High-tech has been a significant profit contributor to Yongtai Technology, accounting for over half of its profits [2] Group 3: Business Overview - Yongtai High-tech, established in June 2016, focuses on new material technology research and production of chemical products, being a key player in the lithium battery electrolyte sector [3] - Yongtai Technology is a leading enterprise in the fluorine fine chemical field, with a focus on lithium battery electrolyte core materials, holding a significant market share in products like lithium hexafluorophosphate and LiFSI [3] Group 4: Financial Performance - In 2022, Yongtai Technology reported revenues of 6.336 billion yuan and a net profit of 554 million yuan [4] - However, in 2023 and 2024, revenues are projected to decline to 4.128 billion yuan and 4.589 billion yuan, with net losses of 620 million yuan and 478 million yuan respectively [4] - The company anticipates a recovery in 2025, with expected revenues of 5 to 5.5 billion yuan and a reduced net loss of 25.6 to 48.6 million yuan, driven by demand in the new energy vehicle and energy storage sectors [4]

而葛卫东另一位关联人王萍持股则保持稳定，截至1月26日，王萍仍持有1148.92万股麦格米特，与去年 底持股数量相同。仅因定增股本稀释，持股比例被动降至1.98%，变为麦格米特第五大股东。 从投资路径来看，葛卫东家族近年来尤为青睐AI产业标的。目前葛卫东不仅是兆易创新的第三大股 东，还是沐曦股份的最大外部股东，与混沌投资合计持有其2693.79万股。 值得注意的是，在葛卫东申购失利的同时，其关联人葛贵莲也退出了麦格米特前十大股东名单。 据了解，葛贵莲是在2025年三季度末新进成为麦格米特的第九大股东，持有麦格米特606.76万股，持股 比例为1.1%，直到2025年底持股数量未发生变化。而此次定增完成后（截止1月26日），麦格米特第十 大股东最新持股数量为529.98万股。以此参照，2026开年以来葛贵莲至少减持麦格米特76万股。 2月5日，麦格米特发布了股票发行上市公告以及最新股东名单。麦格米特此次定增以85.01元/股的价格 向10名对象发行约3132.59万股，合计募集资金26.63亿元。 申购名单显示，葛卫东也参与了麦格米特此次定增，申购总金额高达24亿元，分别出价83.7元、79.98 元、75.6 ...

若按公认会计准则，预计录得经营利润为2亿元（约0.29亿美元）至7亿元（约1亿美元），而去年同期 蔚来录得净亏损55.436亿元。这也是蔚来自2014年11月成立以来首次实现季度盈利。 2月5日晚，蔚来发布盈利预告，在非公认会计准则下，预计蔚来于2025年第四季度录得经调整经营利润 7亿元（约1亿美元）至12亿元（约1.72亿美元）。 事实上，蔚来此次季度扭亏早有迹象。2025年第三季度蔚来实现营收217.94亿元，同比增长16.7%；亏 损同比收窄31.2%至34.81亿元，综合毛利率升至13.9%，汽车业务毛利率为14.7%，均为近三年来最高， 并且经营性现金流也在该季度实现转正。 此前李斌已多次公开表示，蔚来有信心在2025年四季度实现盈利，同时，李斌还提出"2026年蔚来要实 现全年盈利"的目标。 或受利好消息提振，6日盘中，蔚来港股一度涨超8%，收盘涨约6.95%，公司最新市值为967.2亿港元。 进入2026年，销量增长势头延续。今年1月，蔚来累计交付新车2.71万台，同比增长96.1%，全新ES8单 月交付达1.76万辆。 同时，蔚来还在持续优化高端、大车的占比，并计划在今年推出ES9、全新ES ...

Group 1: Industry Overview - The Chinese traditional medicine industry is experiencing a performance recovery, with several leading companies like Yiling and Jiangzhong releasing positive profit growth signals due to marketing reforms, product structure optimization, and cost improvements [1] - Policies such as "Opinions on Improving the Quality of Traditional Chinese Medicine" are creating market opportunities for compliant enterprises, while demographic trends like aging population and the consumption upgrade from Generation Z are driving demand [1] - The population aged 78 and above in China is projected to increase from 32-33 million to 360 million in 25 years, indicating a strong and sustained demand for conservative treatments for chronic diseases [1] Group 2: Company Performance - Tianshili's forecast for 2025 indicates a net profit of 1.105 billion yuan, representing a year-on-year increase of 15.68% [1] - In the first three quarters, Tianshili's pharmaceutical industrial revenue reached 5.709 billion yuan, maintaining stability, with a net profit of 984 million yuan, reflecting a year-on-year growth of 16.88% [2] - The cardiovascular/metabolism segment generated 3.186 billion yuan in revenue during the same period, showing a slight year-on-year growth of 1.16% [2] Group 3: Innovation and Strategic Development - After becoming a member of China Resources Sanjiu, Tianshili has successfully completed a hundred-day integration process, focusing on value, business, organizational, and spiritual restructuring [3] - Tianshili is positioned as the "innovation-driven" wing of the "one body, two wings" strategy, with 31 innovative drugs currently in the research pipeline, including nearly 20 products in late-stage clinical trials [3] - Analysts believe Tianshili's focus on three core disease areas and its rich R&D pipeline present opportunities for value reassessment, with expectations for stable growth in its main business as new products are approved and launched [3]

Group 1 - China Ping An increased its stake in China Pacific Insurance (CPIC) by acquiring approximately 10.89 million H-shares at an average price of about HKD 33.26 per share, totaling around HKD 362 million, raising its holding to approximately 753 million shares, which is 10.12% of the total [1] - China Ping An has been consistently increasing its stake in China Life Insurance since it first acquired shares in August 2025, recently purchasing 11.89 million H-shares for about HKD 381 million, bringing its stake to 9.14%, close to the 10% threshold [1] - China Life Insurance reported a total revenue of CNY 1.28 trillion in 2025, a year-on-year increase of 11.3%, with combined premium income of CNY 887.4 billion, up 7.4%, and total assets of CNY 8.56 trillion, reflecting a 14.4% growth [1] Group 2 - Foreign investment institutions are optimistic about the insurance sector, with Citigroup indicating that retail investors will seek higher reinvestment yields as bank deposits mature, predicting a historic opportunity for life insurance stocks, particularly for leading companies like China Life [2] - China Ping An has also been actively increasing its holdings in state-owned banks, with over 10 instances of increasing stakes in Agricultural Bank, China Merchants Bank, and Postal Savings Bank since 2025, with its stake in Agricultural Bank rising from 5% in February last year to 20.1% by year-end [2] - The trend of increasing equity asset investments by insurance funds is driven by multiple factors, including declining market interest rates and regulatory guidance, making bank stocks attractive due to their large asset sizes and stable dividend returns, similar to the investment logic for insurance stocks [2]

Group 1 - The core point of the article is that Guoxuan High-Tech plans to raise up to 5 billion yuan through a private placement of shares to expand its production capacity in response to the explosive growth in the new energy industry and increasing demand for lithium batteries [1] - The company intends to allocate 2 billion yuan for a 20GWh power battery project, 1 billion yuan for a 20GWh new energy battery base project, and 1 billion yuan for a new lithium-ion battery manufacturing base project, along with working capital [1] - Guoxuan High-Tech has established eight R&D centers globally and is advancing the design of a 2GWh production line, with its high-density quasi-solid-state battery entering the adaptation phase with several automotive companies [1] Group 2 - In terms of performance, Guoxuan High-Tech achieved a revenue of 29.51 billion yuan in the first three quarters of last year, a year-on-year increase of 17.21%, and a net profit attributable to shareholders of 2.533 billion yuan, a significant increase of 514.35% [2] - The company expects to achieve a net profit of approximately 2.5 billion to 3 billion yuan in 2025, representing a growth of 107.16% to 148.59% compared to the previous year's 1.207 billion yuan [2] - However, the non-recurring net profit is projected to be relatively modest at 350 million to 450 million yuan, with a year-on-year growth of 33.31% to 71.40%, indicating a significant gap compared to the net profit attributable to shareholders [2]

公开资料显示，叮咚买菜是国内领先的生鲜即时零售平台，主打"最快29分钟送达"，于2021年登陆纽交 所。截至2025年9月，叮咚买菜在国内共运营约1000个前置仓，月购买用户超过700万。主做华东市场 （江浙沪），在华东自营前置仓的市场占有率超过30%。 财务方面，叮咚买菜已在2024年实现在GAAP标准下全年盈利。当年实现营收230.7亿元，同比增长 15.5%；GMV达到255.6亿元，同比增长16.3%；净利润达4.2亿元，同比增长8倍以上。 进入2025年，叮咚买菜的业绩延续增长态势。三季度实现营收66.6亿元，创历史季度最高；净利润0.8亿 元，已连续7个季度实现GAAP标准下盈利。 作为收购方的美团，近年也高度重视即时零售业务。 2月5日，美团披露公告称，公司已与转让方及梁昌霖签订股份转让协议，计划以7.17亿美元的初始对 价，收购叮咚买菜中国业务100%股权。 协议显示，叮咚买菜海外业务不在本次交易范围内，将在交割前完成剥离。交易过渡期内，叮咚买菜将 按照交易前的模式继续经营。并约定，在美团净现金不低于1.5亿美元的情况下，转让方可提取不超过 2.8亿美元的资金。若收购顺利完成，叮咚买菜将成为美 ...